scholarly journals Improving Model Performance on the Stratification of Breast Cancer Patients by Integrating Multiscale Genomic Features

2020 ◽  
Vol 2020 ◽  
pp. 1-12
Author(s):  
Yingyi Hao ◽  
Li He ◽  
Yifan Zhou ◽  
Yiru Zhao ◽  
Menglong Li ◽  
...  

In clinical cancer research, it is a hot topic on how to accurately stratify patients based on genomic data. With the development of next-generation sequencing technology, more and more types of genomic features, such as mRNA expression level, can be used to distinguish cancer patients. Previous studies commonly stratified patients by using a single type of genomic features, which can only reflect one aspect of the cancer. In fact, multiscale genomic features will provide more information and may be helpful for clinical prediction. In addition, most of the conventional machine learning algorithms use a handcrafted gene set as features to construct models, which is generally selected by a statistical method with an arbitrary cut-off, e.g., p value < 0.05. The genes in the gene set are not necessarily related to the cancer and will make the model unreliable. Therefore, in our study, we thoroughly investigated the performance of different machine learning methods on stratifying breast cancer patients with a single type of genomic features. Then, we proposed a strategy, which can take into account the degree of correlation between genes and cancer patients, to identify the features from mRNAs and microRNAs, and evaluated the performance of the models with the new combined features of the multiscale genomic features. The results showed that, compared with the models constructed with a single type of features, the models with the multiscale genomic features generated by our proposed method achieved better performance on stratifying the ER status of breast cancer patients. Moreover, we found that the identified multiscale genomic features were closely related to the cancer by gene set enrichment analysis, indicating that our proposed strategy can well reflect the biological relevance of the genes to breast cancer. In conclusion, modelling with multiscale genomic features closely related to the cancer not only can guarantee the prediction performance of the models but also can effectively provide candidate genes for interpreting the mechanisms of cancer.

2020 ◽  
Author(s):  
Bum-Sup Jang ◽  
In Ah Kim

Abstract Background: Using by machine learning algorithms, we aimed to identify the mutated gene set from the whole exome sequencing (WES) data of blood in the cancer, which is associated with overall survival in breast cancer patients.Methods: WES data from 1,181 female breast cancer patients within the UK Biobank cohort was collected. The number of mutations for each gene was summed and defined as the blood-based mutation burden per patient. Using by Long short-term memory (LSTM) machine learning algorithm and a XGBoost—a gradient-boosted tree algorithm, we developed the model to predict patient overall survival. Results: From the UK biobank-breast cancer cohort, most altered genes in blood samples were related with the TP53 pathway. In the LSTM model, the minimum 50 genes were found to predict high vs. low mutation burden. In the XGBoost survival model, the gene-set could predict overall survival showing the concordance index of 0.75 and the scaled Brier-score of 0.146 from the held-out testing set (20%, N=236). In older patients (≥ 56 years), the high mutation group based on this gene-set showed inferior overall survival compared to the low mutation group (log-rank test, P=0.042)Conclusion: The machine learning algorithms revealed the gene-signature in the UK biobank breast cancer cohort. Mutational burden observed in blood was associated with overall survival in relatively old patients. This gene-signature should be verified in prospective setting.


2020 ◽  
Author(s):  
Yang Liu ◽  
Qian Du ◽  
Dan Sun ◽  
Ruiying Han ◽  
Mengmeng Teng ◽  
...  

Abstract Background: SQSTM1 (Sequestosome 1, p62) is degraded by activated autophagy and involved in the progression of in various types of cancers. However, the prognostic role and underlying regulation mechanism of SQSTM1 in the progression and development of breast cancer remain unclear.Methods: In this study, 1336 samples with available mRNA data from Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) database and 27 formalin fixation and paraffin embedding (FFPE) tissue samples from the First Affiliated Hospital of Xi’an Jiaotong University were collected to evaluate SQSTM1 expression in mRNA and protein levels. Kaplan–Meier and Cox regression were used for revealing prognostic value in three independent breast cancer independent datasets. Tumor Immune Estimation Resource (TIMER) database and Gene Set Variation Analysis (GSVA) was used to explore the relationship of SQSTM1 mRNA expression and immune infiltration level in breast cancer. Dysregulation mechanisms of SQSTM1 were also explored including copy number variation (CNV), somatic mutation, epigenetic alterations and other transcription and post-transcription level using multiple datasets. Finally, Gene Set Enrichment Analysis (GSEA) was constructed to elucidate functional regulating performance of SQSTM1 in breast cancer.Results: The results showed that mRNA and protein level of SQSTM1 were significantly elevated in breast cancer and receiver operating characteristic (ROC) curve showed that p62 may act as diagnostic biomarker. Lower expression of SQSTM1 predicted better outcome through multiple datasets. It was also found that SQSTM1 correlated with immune infiltrates in breast cancer. Moreover, CNV and methylation of SQSTM1 DNA was correlated with SQSTM1 dysregulation and act as prognostic factors for breast cancer patients. Yet, somatic mutation status of SQSTM1 didn’t show any prognostic relevance. We also identified diverse transcription factors that directly bound to SQSTM1 DNA and the miRNAs which may regulate SQSTM1 mRNA. Finally, functional enrichment analysis revealed that SQSTM1 is related to cell signal transduction, oxidative stress and autophagy in breast cancer.Conclusion: Our findings revealed that SQSTM1 plays a key role in the progression of breast cancer and might be a promising biomarker for the diagnosis and personalized treatment of breast cancer patients.


2020 ◽  
Author(s):  
Yang Liu ◽  
Qian Du ◽  
Dan Sun ◽  
Ruiying Han ◽  
Mengmeng Teng ◽  
...  

Abstract Background: SQSTM1 (Sequestosome 1, p62) is degraded by activated autophagy and involved in the progression of in various types of cancers. However, the prognostic role and underlying regulation mechanism of SQSTM1 in the progression and development of breast cancer remain unclear.Methods: In this study, 1336 samples with available mRNA data from Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) database and 27 formalin fixation and paraffin embedding (FFPE) tissue samples from the First Affiliated Hospital of Xi’an Jiaotong University were collected to evaluate SQSTM1 expression in mRNA and protein levels. Kaplan–Meier and Cox regression were used for revealing prognostic value in three independent breast cancer independent datasets. Tumor Immune Estimation Resource (TIMER) database and Gene Set Variation Analysis (GSVA) was used to explore the relationship of SQSTM1 mRNA expression and immune infiltration level in breast cancer. Dysregulation mechanisms of SQSTM1 were also explored including copy number variation (CNV), somatic mutation, epigenetic alterations and other transcription and post-transcription level using multiple datasets. Finally, Gene Set Enrichment Analysis (GSEA) was constructed to elucidate functional regulating performance of SQSTM1 in breast cancer.Results: The results showed that mRNA and protein level of SQSTM1 were significantly elevated in breast cancer and receiver operating characteristic (ROC) curve showed that p62 may act as diagnostic biomarker. Lower expression of SQSTM1 predicted better outcome through multiple datasets. It was also found that SQSTM1 correlated with immune infiltrates in breast cancer. Moreover, CNV and methylation of SQSTM1 DNA was correlated with SQSTM1 dysregulation and act as prognostic factors for breast cancer patients. Yet, somatic mutation status of SQSTM1 didn’t show any prognostic relevance. We also identified diverse transcription factors that directly bound to SQSTM1 DNA and the miRNAs which may regulate SQSTM1 mRNA. Finally, functional enrichment analysis revealed that SQSTM1 is related to cell signal transduction, oxidative stress and autophagy in breast cancer.Conclusion: Our findings revealed that overexpression of SQSTM1 significantly to poor survival and immune infiltrations in breast cancer. In addition, SQSTM1 plays a key role in the progression of breast cancer and might be a promising biomarker for the diagnosis and personalized treatment of breast cancer patients.


2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12567-e12567
Author(s):  
Hao Yu ◽  
Fang Chen ◽  
Li Yang ◽  
Jian-Yue Jin ◽  
Feng-Ming Spring Kong

e12567 Background: Radiation-induced lymphopenia accompanied with radiation therapy is associated with inferior clinical outcomes in a wide variety of solid malignancies. This study aimed to examine the potential determines of radiation-induced lymphocyte decrease and radiation-induced lymphopenia in breast cancer patients who underwent radiotherapy. Methods: Patients with breast cancer treated who underwent radiotherapy were enrolled in University of Hong Kong-Shenzhen Hospital (our cohort). Circulating lymphocyte levels were evaluated within 7 days prior to and end of radiation therapy. Feature groups including clinical data, tumor characteristics, radiotherapy dosimetrics, treatment regiments were also collected. We applied machine learning algorithms (Extreme Gradient Boosting, XGboost) to predict the ratio of lymphocyte level after radiotherapy to baseline lymphocyte level and the event of lymphopenia and compared with Lasso regression approaches. Next, we used Shapley additive explanation (SHAP) to explore the directional contribution of each feature for lymphocyte decrease and lymphopenia. For the purpose of model validation and proof-of-concept validation, an independent cohort of patients enrolled in prospective trial was eligible (IP cohort). Results: A total of 589 patients were enrolled in our cohort and 203 patients in IP cohort. XGboost models which trained in our cohort with performances of a mean RMSE: 0.157 and R2: 53.9% for the ratio of lymphocyte levels; a mean accuracy: 0.757 and ROC-AUC: 0.733 for the lymphopenia events, separately. These models can predict the ratio of lymphocyte levels with a mean RMSE: 0.175 and R2: 47%; predict the lymphopenia events with a mean accuracy: 0.739 and ROC-AUC: 0.737 in the totally independent IP cohort. The feature group of dosimetrics had the largest predictive power with RMSE: 0.192, R2: 29.8%, accuracy: 0.678 and ROC-AUC: 0.667; followed by the group of baseline blood cells with predictive power as RMSE: 0.207, R2: 18.9%, accuracy: 0.669 and ROC-AUC: 0.645. Next, by SHAP value analysis, we investigated that integral dose of the total body, V5 dose, mean lung dose and V20 dose of ipsilateral lung/bilateral lungs were in consequence important promote factors for lymphocyte decrease and for the event of lymphopenia, while the features of baseline monocyte, mean heart dose and tumor size played a role of protection at some extend. Conclusions: In this study, we constructed robust XGboost models for predicting the lymphocyte decrease and the event of lymphopenia in breast cancer patients who underwent radiation therapy. We also applied SHAP analysis for revealing the directional contribution of features. These results are important either for the understanding the contributions of dosimetrics on immune response or for the refine of radiation dosimetrics before treatment in future clinical usages.


2021 ◽  
Vol 12 (4) ◽  
pp. 117-137
Author(s):  
Mazen Mobtasem El-Lamey ◽  
Mohab Mohammed Eid ◽  
Muhammad Gamal ◽  
Nour-Elhoda Mohamed Bishady ◽  
Ali Wagdy Mohamed

There are many cancer patients, especially breast cancer patients as it is the most common type of cancer. Due to the huge number of breast cancer patients, many breast cancer-focused hospitals aren't able to process the huge number of patients and might expose some women to late stages of cancer. Thus, the automation of the process can help these hospitals in speeding up the process of cancer detection. In this paper, the authors test several machine learning models such as k-nearest neighbours (KNN), support vector machine (SVM), and artificial neural network (ANN). They then compare their accuracies and losses with themselves and other models that have been developed by other researchers to see whether their approach is efficient or not and to decide what machine learning algorithm is best to use.


2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Roqia Saleem Awad Maabreh ◽  
Malik Bader Alazzam ◽  
Ahmed S. AlGhamdi

Today, cancer is the second leading cause of death worldwide, and the number of people diagnosed with the disease is expected to rise. Breast cancer is the most commonly diagnosed cancer in women, and it has one of the highest survival rates when treated properly. Because the effectiveness and, as a result, survival of the patient are dependent on each case, it is critical to know the modelling of their survival ahead of time. Artificial intelligence is a rapidly expanding field, and its clinical applications are following suit (having surpassed humans in many evidence-based medical tasks). From the inception of since first stable risk estimator based on statistical methods appeared in survival analysis, there have been numerous versions of it created, with machine learning being used in only a few of them. Nonlinear relationships between variables and the impact they have on the variable to be predicted are very easy to evaluate using statistical methods. However, because they are just mathematical equations, they have flaws that limit the quality of their output. The main goal of this study is to find the best machine learning algorithms for predicting the individualised survival of breast cancer patients, as well as the most appropriate treatment, and to propose new numerical variable stratifications. They will still be carried out using unsupervised machine learning methods that divide patients into groups based on their risk in each dataset. We will compare it to standard groupings to see if it has more significance. Knowing that the greatest challenge in dealing with clinical data is its quantity and quality, we have gone to great lengths to ensure their quality before replicating them. We used the Cox statistical method in conjunction with other statistical methods and tests to find the best possible dataset with which to train our model, despite its ease of multivariate analysis.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Pratyusha Rakshit ◽  
Onintze Zaballa ◽  
Aritz Pérez ◽  
Elisa Gómez-Inhiesto ◽  
Maria T. Acaiturri-Ayesta ◽  
...  

AbstractThis paper presents a novel machine learning approach to perform an early prediction of the healthcare cost of breast cancer patients. The learning phase of our prediction method considers the following two steps: (1) in the first step, the patients are clustered taking into account the sequences of actions undergoing similar clinical activities and ensuring similar healthcare costs, and (2) a Markov chain is then learned for each group to describe the action-sequences of the patients in the cluster. A two step procedure is undertaken in the prediction phase: (1) first, the healthcare cost of a new patient’s treatment is estimated based on the average healthcare cost of its k-nearest neighbors in each group, and (2) finally, an aggregate measure of the healthcare cost estimated by each group is used as the final predicted cost. Experiments undertaken reveal a mean absolute percentage error as small as 6%, even when half of the clinical records of a patient is available, substantiating the early prediction capability of the proposed method. Comparative analysis substantiates the superiority of the proposed algorithm over the state-of-the-art techniques.


Sign in / Sign up

Export Citation Format

Share Document